PrimeGenX looks to a Hong Kong IPO as a cure for its cash woes
The developer of anti-inflammatory treatments will need to persuade investors to look past its balance sheet problems and its narrow pipeline of products Key Takeaways: The company is making a…
Legend Bio CEO resigns, shares tumble
Drugmaker Legend Biotech Corp. (LEGN.US) said on Monday that Huang Ying resigned as the company’s CEO and member of its board effective July 24, without giving any reason for his departure.…
Insilico revenue soars above $100 million on AI drug partnerships
The developer of the world’s first end-to-end AI drug has projected a big leap in half-year earnings, driven by lucrative collaborations with multinationals Key Takeaways: Insilico expects to power into…
Drug setback leaves Ascletis with an all-in bet on weight loss
The company’s two core hepatitis drugs were dropped from China’s state insurance scheme on July 1, effectively wiping out the remains of its legacy drug sales Key Takeaways: The company…
Alebund soars in Hong Kong debut on kidney treatment hopes
The drug developer stood out from the IPO crowd of unprofitable biotechs due to its existing revenue stream and a focus on novel remedies for renal disease Key Takeaways: Alebund…
CSPC Innovation pursues Hong Kong IPO as parent profits shrink
The producer of food additives and pharmaceutical ingredients is aiming to raise fresh capital to support its drive to become a developer of innovative drugs Key takeaways: R&D costs have…
WuXi AppTec wages buyback campaign as U.S. pressure mounts
The drug services provider has been battling to shore up its share price and suffered a sharp sell-off after being added to a U.S. list of firms with suspected military…
